WARRANT -------Warrant Agreement • March 9th, 2004 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
COMMON STOCK PURCHASE WARRANT RegeneRx Biopharmaceuticals, Inc.Common Stock Purchase Warrant • March 29th, 2018 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier of (i) September 2, 2018 and (ii) the effective date of the registration statement registering for resale the Warrant Shares (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ___________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 6th, 2021 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 28, 2021, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
WITNESSETHServices Agreement • April 23rd, 2004 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
ALPHA RIGHTS ACQUISITION AGREEMENTAcquisition Agreement • January 13th, 1998 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations • California
1 EXHIBIT 10.2 "[ * ]" = omitted, confidential material, which material has been separately filed with the Securities and Exchange Commission pursuant to a request for confidential treatment. SETTLEMENT AGREEMENT AND MUTUAL RELEASE THIS SETTLEMENT...Settlement Agreement • April 2nd, 2001 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations • Maryland
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 6th, 2021 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2021, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
EXHIBIT 10.11 SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 9th, 2004 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
EXHIBIT 99.2Consulting Agreement • November 9th, 1999 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations • Maryland
EXHIBIT 10.26 Registration Rights Agreement This Registration Rights Agreement (the "Agreement") is entered into as of March 12, 1997, by and among Alpha 1 Biomedicals, Inc., a Delaware corporation (the "Company"), and each of the undersigned...Registration Rights Agreement • March 31st, 1997 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations • Maryland
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 7th, 2011 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 4, 2011, by and between REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
WARRANT BWarrant Agreement • January 26th, 2004 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
EXHIBIT 99.3Non-Qualified Stock Option Agreement • November 9th, 1999 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations
COVER PAGEPatent License Agreement • April 2nd, 2001 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations • District of Columbia
RECITALSEmployment Agreement • March 9th, 2004 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Maryland
EXHIBIT 10.25 Unit Purchase Agreement THIS AGREEMENT is made as of March 12, 1997, by and between Alpha 1 Biomedicals, Inc., a Delaware corporation (the "Company"), and each of the investors listed in Schedule 1 attached hereto (hereinafter...Unit Purchase Agreement • March 31st, 1997 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations • Maryland
ContractPlacement Agent Agreement • July 1st, 2016 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
THYMOSIN BETA 4 LICENSE AND SUPPLY AGREEMENT ("AGREEMENT")License and Supply Agreement • March 9th, 2004 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 30th, 2009 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 30, 2009, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENCY AGREEMENT September 30, 2009Placement Agency Agreement • September 30th, 2009 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to (i) 4,512,195 shares (the “Shares”) of its common stock, $0.001 par value per share (the “Common Stock”), and (ii) 2,256,098 warrants to purchase shares of Common Stock (the “Warrants”, and together with the Shares, the “Securities”), to certain investors (each an “Investor” and, collectively, the "Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-150675). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the Warrant Shares. The Securities are more fully described in the Prospectus (as defined below). The Company desires to engage Roth Capital Partners, LLC and Boenning & Scattergood, Inc. in connection with such issuance and sale of the Securities.
11,500,000 UNITS REGENERX BIOPHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 21st, 2010 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
RegeneRx Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), confirms its agreement, subject to the terms and conditions set forth herein, with each of the underwriters listed on Exhibit A hereto (collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), to sell and issue to the Underwriters an aggregate of 11,500,000 units, each unit consisting of one (1) share of common stock, par value of $0.001 (the “Common Shares”), or 11,500,000 shares in the aggregate, and 0.4 of a tradeable warrant to purchase one Common Share, or 4,600,000 warrants in the aggregate, (the “Warrants”) of the Company (each, a “Firm Unit”). The Warrants are being issued pursuant to and shall have the rights and privileges set forth in that certain Warrant Agreement, dated as of the date hereof, between the Company and American Stock Transfer & Trust Company (the “Warrant Agree
COMMON STOCK PURCHASE WARRANT RegeneRx Biopharmaceuticals, Inc.Common Stock Purchase Warrant • July 1st, 2016 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the later of (i) the five and one half year anniversary of the Initial Exercise Date or (ii) the five year anniversary of the date that all Warrant Shares are registered for resale pursuant to an effective Registration Statement (the “Termination Date”) but not thereafter, to subscribe for and purchase from RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), up to 5,147,059 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
RECITALSWarrant Amendment Agreement • September 22nd, 2004 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
EXHIBIT 10.1 FIRST AMENDMENT AGREEMENT to ALPHA RIGHTS ACQUISITION AGREEMENTFirst Amendment Agreement • May 20th, 1998 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations
SERIES A COMMON STOCK PURCHASE WARRANT REGENERX BIOPHARMACEUTICALS, INC.Series a Common Stock Purchase Warrant • August 6th, 2021 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 30, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Amended and Restated Change in Control AgreementChange in Control Agreement • August 14th, 2012 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Maryland
This Amended and Restated Change in Control Agreement (this “Agreement”) is effective as of July 2, 2012, by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and J.J. Finkelstein (the “Executive”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKWarrant Agreement • November 13th, 2020 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, _____________, or his permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to _____________shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase Agreement”).
PURCHASE AGREEMENTPurchase Agreement • January 6th, 2005 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
THIS PURCHASE AGREEMENT is made as of December , 2004, by and between REGENERX BIOPHARMACEUTICALS, INC. (the “Company”), a corporation organized under the laws of the State of Delaware, with its principal offices at 3 Bethesda Metro Center, Suite 700, Bethesda, Maryland 20814 and the purchaser whose name and address is set forth on the signature page hereof (the “Purchaser”).
EXHIBIT 10.10 LEASE AND SERVICE AGREEMENT This Agreement is made this 24th day of August, 1999, by and between VANTAS, 3 Metro Bethesda, Inc., d/b/a VANTAS ("Lessor") having offices known and numbered as Suite 700 (the "Facility") in the building...Lease and Service Agreement • November 8th, 2000 • Alpha 1 Biomedicals Inc • Pharmaceutical preparations
REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT October 15, 2020Convertible Note and Warrant Purchase Agreement • November 13th, 2020 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
THIS CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), dated as of October 15, 2020, is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and XXXX (the “Investor”).
REGENERX BIOPHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT JANUARY 5, 2011Securities Purchase Agreement • January 7th, 2011 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 5, 2011, is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Sinaf S.A. (the “Investor”).
rgn-137 LICENSE AgreementLicense Agreement • May 15th, 2014 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This License Agreement (this “Agreement” or this “License Agreement”) is effective as of March 7, 2014 (the “Effective Date”) by and between RegeneRx Biopharmaceuticals, Inc., a company organized and existing under the laws of the state of Delaware, with offices at 15245 Shady Grove Road, Suite 470, Rockville, Maryland, U.S.A. (hereinafter “Licensor”), and Digital Aria Co., Ltd. with offices at 22nd FL, Parkview Tower, 248 Jungjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-863, Republic of Korea (hereinafter “Licensee”), each a “Party” and, collectively, the “Parties.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 18th, 2006 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 15, 2006, by and among RegeneRx Biopharmaceuticals, Inc, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR...Warrant Agreement • May 21st, 2010 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This WARRANT (this “Warrant”) of RegeneRx Biopharmaceuticals, Inc., a corporation duly organized and validly existing under the laws of the State of Delaware (the “Company”), is being issued pursuant to that certain Underwriting Agreement, dated as of May 17, 2010, by and between the Company and Maxim Group LLC, the representative of the underwriters (the “Representative”) relating to a firm commitment public offering (the “Offering”) of an aggregate of 11,500,000 units, each unit consisting of (i) one share of common stock, par value of $0.001 of the Company (each a “Common Share” and collectively, the “Common Shares”) and (ii) 0.4 Warrants to purchase one Common Share.
Re: First Amendment to Temporary Employment TermsTemporary Employment Terms • January 8th, 2013 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
This letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. ( “Company”) that were set forth in that Temporary Employment Terms Letter Agreement dated July 2, 2012, executed by you and the Company (collectively, the “Employment Agreement”). As provided at the end of this letter, you may accept this Amendment by signing and returning to us a counterpart copy of this letter, which signature and return will result in this Amendment being binding between the Company and you as to the matters set forth herein, as of January 1, 2013 (the “Effective Date”). Defined terms that are not defined herein shall have the meaning assigned to them in the Employment Agreement.
